Efficacy of infliximab in refractory ankylosing spondylitis: Results of a six-month open-label study

Rheumatology

Volumn 41, Issue 11, 2002, Pages 1280-1285

  Breban, M ^a,b   Vignon, E ^c   Claudepierre, P ^d   Devauchelle, V ^e   Wendling, D ^f   Lespessailles, E ^g   Euller Ziegler, L ^h   Sibilia, J ⁱ   Perdriger, A ^j   Mezieres M ^a   Alexandre, C ^k   Dougados, M ^a  

^a Institut de Rhumatologie Hopital Cochin   (France)

^b Centre Hospitalier Lyon Sud ^*  (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e SERVICE DE RHUMATOLOGIE   (France)

^f UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^g Centre Hospitalier Régional   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ HÔPITAL DE HAUTEPIERRE   (France)

^j SERVICE DE RHUMATOLOGIE   (France)

^k SERVICE DE NEUROLOGIE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; THIOL DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; OTITIS MEDIA; PAIN ASSESSMENT; PHARYNGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; RHINITIS; SIDE EFFECT; SINUSITIS; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036852331     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondylarthropathies. Rheum Dis Clin North Am 1995; 21:117-28.
2. Ferraz MB, Tugwell P, Goldsmith CH, Atra E. Metaanalysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990;17:1482-6.
3. Dougados M, van der Linden S, Leirisalo-Repo M et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
4. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1640-1.
5. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385-90.
6. D'haens G, Van Deventer S, Van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999; 116:1029-34.
7. Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
8. Breban M, Gombert B, Amor B, Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 1999;42:580-1.
9. Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
10. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy. Arthritis Rheum 2001;44:2112-7.
11. Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 2001;13:245-9.
12. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
13. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index, J Rheumatol 1994; 21:2286-91.
14. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
15. Lent L, Hahn L, Eremenco S, Webster K, Cella D. Using cross-cultural input to adapt the Functional Assessment of Chronic Illness Therapy (FACIT) scales. Acta Oncol 1999;38:695-702.
16. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44:1876-86.
17. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59:428-33.
18. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001;28:1605-14.
19. Matthys P, Billian A. Cytokines and cachexia. Nutrition 1997;13:763-70.
20. Mielants H, Veys E, Cuvelier C, de Vos M. Course of gut inflammation in spondylarthropathies and therapeutic consequences. Bailliere's Clin Rheumatol 1996;10:147-64.
21. Stafford L, Kane D, Murphy E et al. Psoriasis predicts a poor short-term outcome in patients with spondylarthropathy. Arthritis Rheum 2001;45:485-93.
22. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.